• linkedin
  • Increase Font
  • Sharebar

    Infection risk from biologics deserves careful scrutiny

    Denver — Although relatively healthy patients taking biologic drugs for psoriasis generally face a low risk of infection, an expert says, patients with additional risk factors should proceed cautiously.

    Because biologic drugs impact the immune system, says Kenneth B. Gordon, M.D., the most important safety question physicians and patients usually ask is whether these drugs increase infection risks. However, he adds, discussing safety and risks outside the context of biologic benefits may needlessly alarm patients. Dr. Gordon is a professor of dermatology at Northwestern University Feinberg School of Medicine, Chicago.

    Physicians cannot assess the safety of a treatment for a particular patient in a vacuum, Dr. Gordon says. The way a physician interprets data strongly impacts what he or she tells patients about biologic drugs’ safety.

    “We try to generalize. But the most important thing is to think about the patient in front of you,” he says.

    With any therapy, Dr. Gordon says, “We’re trying to improve the patient’s general health. And highlighting one little area — such as infection, malignancy or cardiovascular disease — as a single entity loses the big picture.”

    Next: Risk factors


    John Jesitus
    John Jesitus is a medical writer based in Westminster, CO.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow